FDA tackles women's sexual health

Share this article:

The FDA is taking on female sexual dysfunction. Regulatory Focus reports that the regulator will be asking patients questions about the collection of conditions known by the shorthand FSD during a two-day hearing in October.

The meeting is being convened as part of the FDA's Patient-Focused Drug Development process, which is intended to be a way for the FDA to take into consideration the risks patients say they are willing to take on, as opposed to considering only risk/benefit tradeoffs with which the regulator is comfortable.

A coalition of healthcare groups has been urging the FDA to put women's sexual health concerns on par with those of men, and kicked off an awareness campaign in June to spur action.

RF says that while FDA has yet to share the questions it expects to ask, the hearing will take place on October 27 and October 28.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.